VENICE REGIONAL BAYFRONT HEALTH
1. Target Overview & Investment Thesis
VENICE REGIONAL BAYFRONT HEALTH is a 229-bed under-performing / distressed in SARASOTA, FL with $85.7M in net patient revenue and a -20.2% operating margin. The hospital serves a payer mix of 41.8% Medicare, 4.9% Medicaid, and 53.3% commercial.
Thesis: Undervalued. Our ML models identify $6.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -20.2% to -12.8% (+736bps).
| Net Revenue HCRIS | $85.7M |
| Current EBITDA COMPUTED | $-17.3M |
| Operating Margin COMPUTED | -20.2% |
| Occupancy HCRIS | 24.7% |
| Revenue / Bed COMPUTED | $374K |
| Net-to-Gross HCRIS | 10.1% |
| Distress Probability ML | 54.2% |
2. Market Context & Competitive Position
FL has 261 Medicare-certified hospitals with a median operating margin of 3.2%. The target's margin of -20.2% places it below the state median. Among 114 size-comparable peers (114-458 beds), the median margin is 4.4%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (114-458), prioritizing same-state peers. 114 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| VENICE REGIONAL BAYFRONT HEALT (Target) | FL | 229 | $85.7M | -20.2% |
| MOFFITT CANCER CENTER | FL | 218 | $1.91B | 16.0% |
| MAYO CLINIC FLORIDA | FL | 304 | $1.09B | 21.6% |
| NICKLAUS CHILDRENS HOSPITAL | FL | 259 | $769.3M | 5.5% |
| SOUTH MIAMI HOSPITAL | FL | 375 | $688.4M | 11.6% |
| BOCA RATON REGIONAL HOSPITAL | FL | 361 | $609.5M | -9.6% |
| JOHNS HOPKINS ALL CHILDRENS HO | FL | 259 | $584.5M | -10.3% |
| HOLY CROSS HOSPITAL | FL | 286 | $566.3M | -0.7% |
| HCA FLORIDA KENDALL HOSPITAL | FL | 424 | $541.2M | 35.2% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.3M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.8M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.7M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.7M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.0M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $55K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-17.3M |
| + RCM Uplift | +$6.3M |
| Pro Forma EBITDA | $-11.0M |
| Current Margin | -20.2% |
| Pro Forma Margin | -12.8% |
| WC Released (1x) | $3.3M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-26.6M | $-51.1M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-26.6M | $-64.9M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-24.0M | $-52.7M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-24.0M | $-64.6M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-29.3M | $-74.0M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-29.3M | $-90.9M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Low occupancy | At 24.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 54.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 114 hospitals with 114-458 beds
- Same-state prioritization (n=115)
- Comp margins: P25=-4.2% / P50=4.4% / P75=16.9%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.